A prospective, randomized clinical trial was conducted to evaluate the efficacy of endocrine chemotherapy with uracil and tegafur (in a molar ratio of 4:1 [UFT]) in patients with prostate cancer. The study included two
Manabu Kuriyama, MD, PhD
Advertisement
Articles by Manabu Kuriyama, MD, PhD
Advertisement
Latest Updated Articles
- Endocrine Plus Uracil/Tegafur Therapy for Prostate Cancer
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
3
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
4
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
5
